Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
Long-term disease control in multiple myeloma by in-class transitioning: A commu...
Dr Robert Rifkin - Rocky Mountain Cancer Centers, Denver, USA
Long-term disease control in multiple myeloma by in-class transitioning: A community-based study ( Dr Robert Rifkin - Rocky Mountain Cancer Centers, Denver, USA )
3 Jul 2020
Venetoclax plus navitoclax in R/R ALL and lymphoblastic lymphoma
Dr Elias Jabbour - MD Anderson Cancer Center, Houston, USA
Venetoclax plus navitoclax in R/R ALL and lymphoblastic lymphoma ( Dr Elias Jabbour -  MD Anderson Cancer Center, Houston, USA )
3 Jul 2020
The future of PARP inhibitors in prostate cancer
Dr Elena Castro - Spanish National Cancer Research Center, Madrid, Spain
The future of PARP inhibitors in prostate cancer ( Dr Elena Castro - Spanish National Cancer Research Center, Madrid, Spain )
2 Jul 2020
IMvigor130: Atezolizumab with or without chemotherapy in metastatic urothelial c...
Prof Matthew Galsky - The Mount Sinai Hospital, New York, USA
IMvigor130: Atezolizumab with or without chemotherapy in metastatic urothelial cancer ( Prof Matthew Galsky - The Mount Sinai Hospital, New York, USA )
30 Jun 2020
Checkmate 9LA: Nivolumab, ipilimumab and chemotherapy for stage IV NSCLC
Prof Martin Reck - Lung Clinic Grosshansdorf, Grosshansdorf, Germany
Checkmate 9LA: Nivolumab, ipilimumab and chemotherapy for stage IV NSCLC ( Prof Martin Reck - Lung Clinic Grosshansdorf, Grosshansdorf, Germany )
30 Jun 2020
Treating patients with multiple myeloma in the real world
Dr Ajai Chari and Prof Roman Hájek
Treating patients with multiple myeloma in the real world ( Dr Ajai Chari and Prof Roman Hájek )
26 Jun 2020
ASCEND final results: Acalabrutinib vs idelalisib plus rituximab or bendamustine...
Prof Paolo Ghia - Vita-Salute San Raffaele University, Milan, Italy
ASCEND final results: Acalabrutinib vs idelalisib plus rituximab or bendamustine plus rituximab in R/R CLL ( Prof Paolo Ghia - Vita-Salute San Raffaele University, Milan, Italy )
26 Jun 2020
KarMMa: Idecabtagene vicleucel in patients with r/r multiple myeloma
Prof Jesús San Miguel - Universidad de Navarra, Pamplona, Spain
KarMMa: Idecabtagene vicleucel in patients with r/r multiple myeloma ( Prof Jesús San Miguel - Universidad de Navarra, Pamplona, Spain )
26 Jun 2020
LOW-PV interim analysis: Ropeginterferon versus phlebotomy in low-risk polycythe...
Prof Tiziano Barbui - FROM Research Foundation, Bergamo, Italy
LOW-PV interim analysis: Ropeginterferon versus phlebotomy in low-risk polycythemia vera ( Prof Tiziano Barbui - FROM Research Foundation, Bergamo, Italy )
25 Jun 2020
ASCO 2020: Updates in non-metastatic castration-resistant prostate cancer
Prof Boris Hadaschik - University of Duisburg-Essen, Essen, Germany
ASCO 2020: Updates in non-metastatic castration-resistant prostate cancer ( Prof Boris Hadaschik - University of Duisburg-Essen, Essen, Germany )
24 Jun 2020
Maintenance treatment in multiple myeloma: A new era
Prof Sagar Lonial and Prof Wee-Joo Chng
Maintenance treatment in multiple myeloma: A new era ( Prof Sagar Lonial and Prof Wee-Joo Chng )
18 Jun 2020
CITYSCAPE: Tiragolumab plus atezolizumab for non-small cell lung cancer
Dr Melissa Johnson - Sarah Cannon Research Institute, Nashville, USA
CITYSCAPE: Tiragolumab plus atezolizumab for non-small cell lung cancer ( Dr Melissa Johnson - Sarah Cannon Research Institute, Nashville, USA )
17 Jun 2020